Abstract
Oral carcinoma (OC) remains one of the most difficult malignancies to cure. Hesa-A is an Iranian herbal-marine compound that has shown promising anti-tumor properties against various human tumors. However, its mechanism of action remains to be addressed. The present study was conducted to evaluate the effect of two doses of Hesa-A on mRNA expression of erb\b2 as a main prognosticator tumor marker for OC in an animal model. A total of 60 rats were randomly divided into 5 groups of 12 animals each. Rats in carcinoma groups received 0, 250 and 500 mg/kg body weight doses of Hesa-A 3 times a day. The other two groups were considered as treated and untreated control groups. At the end of the experiment, animals were sacrificed and tongue tissues subjected to H and E staining and real time PCR. Our results showed that compared to the control group, erb\ b2 was over-expressed ~ 30% in the carcinoma group. After treatment with 250 mg/kg and 500 mg/kg body weight of Hesa-A , erb\b2 levels dropped by 24.1% and 3.4 % respectively compared to the control carcinoma group (p<0.01, p<0.0001). Moreover, there was a significant relation between erb\ b2 mRNA content and observed pathological changes in studied groups (p<0.05). These data provide insight into mechanism(s) by which Hesa-A may improve clinical outcome of oral carcinoma by affecting oncogene erb\b2 expression and suggest Hesa-A as an effective chemotherapeutic agent in treatment of HER+ tumors.
Highlights
Oral cavity cancers are rather common and rank eleventh among other cancers all over the world (Zwetyenga et al, 2003)
Our results showed that compared to the control group, erb\ b2 was over-expressed ~ 30% in the carcinoma group
After treatment with 250mg/kg and 500mg/kg body weight of Hesa-A, erb\b2 levels dropped by 24.1% and 3.4 % respectively compared to the control carcinoma group (p
Summary
Oral cavity cancers are rather common and rank eleventh among other cancers all over the world (Zwetyenga et al, 2003). Tongue cancer is the most common oral cavity neoplasm with an unfavorable prognosis and high metastatic potential (Mesgari et al, 2014). Studies on anti-neoplastic properties of Hesa-A showed promising results in patients with advanced colorectal cancer and end staged breast cancer patients with choroidal metastasis (Ahmadi et al, 2005; Ahmadi et al, 2009). Its overexpression is common in many malignancies, including breast, prostate, lung, and bladder cancers, correlating with poor prognosis (Lippman and Hong, 2001). Hesa-A showed satisfactory results in some end staged and metastatic tumors, its effects still need to be tested on other aggressive tumors including oral carcinoma. In following study we evaluated the therapeutic effects of two doses of Hesa-A on erb\ b2 expression as a main prognosticator for oral cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
